Sierra Oncology, Inc. (SRRA) News

Sierra Oncology, Inc. (SRRA): $14.74

0.27 (+1.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

Filter SRRA News Items

SRRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SRRA News Highlights

  • For SRRA, its 30 day story count is now at 2.
  • Over the past 13 days, the trend for SRRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about SRRA are RARE.

Latest SRRA News From Around the Web

Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.

Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.

Yahoo | February 9, 2021

Sierra Oncology: Time To Enter For The Big Pie

There are only a few things that make a compelling argument in favour of investing in development stage companies. A deep pipeline, a big unmet need in the market, or a proximity to commercialisation are usually the business side checkpoints, while an unreasonably sustained dip in the stock price is...

Siva Kumar Raju Kolaru on Seeking Alpha | January 27, 2021

Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021.

Yahoo | January 5, 2021

Is SRRA A Good Stock To Buy Now?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]

Yahoo | December 11, 2020

Who Has Been Buying Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

Yahoo | November 18, 2020

Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the Jefferies Virtual London Healthcare Conference taking place November 17-19, 2020.

Yahoo | November 12, 2020

Karyopharm Therapeutics (NASDAQ:KPTI) versus Sierra Oncology (NASDAQ:SRRA) Head-To-Head Contrast

Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]

Daily Political | October 24, 2020

Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) Critical Contrast

Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]

US Banking News | October 22, 2020

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointments of Mr. Kevin Norrett as Chief Business Officer and Mr. William D. Turner as Chief Regulatory and Technical Operations Officer.

Yahoo | August 6, 2020

Sierra Oncology Reports Second Quarter 2020 Results

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today reported its financial and operational results for the second quarter ended June 30, 2020.

Yahoo | August 6, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.545 seconds.